Stoke Therapeutics (STOK) to Release Earnings on Monday

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect Stoke Therapeutics to post earnings of ($0.42) per share and revenue of $27.37 million for the quarter.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. On average, analysts expect Stoke Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Stoke Therapeutics Stock Down 2.4 %

Shares of NASDAQ STOK traded down $0.24 during midday trading on Friday, reaching $9.63. 640,908 shares of the company's stock traded hands, compared to its average volume of 868,015. The stock's 50 day simple moving average is $7.87 and its 200-day simple moving average is $10.22. The company has a market cap of $525.77 million, a price-to-earnings ratio of -4.59 and a beta of 1.09. Stoke Therapeutics has a one year low of $5.35 and a one year high of $17.58.

Insider Buying and Selling at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 over the last 90 days. 11.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Chardan Capital restated a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $24.67.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.